Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure

Trial Profile

Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs C3BS CQR 1 (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CHART-1
  • Sponsors Celyad
  • Most Recent Events

    • 11 May 2017 According to a Celyad media release, the 12 months data recently presented by Prof. John Teerlink at the late breaking session of the European Heart Failure Society meeting (Paris, May 1st, 2017), and accepted for publication in the European Journal of Heart Failure.
    • 11 May 2017 According to a Celyad media release, U.S. Food and Drug Administration (FDA) has granted Fast Track designation for C-Cure therapy based on the evidence in the subset of patients that were responders at 9 month, further confirmed by the 12 months data of this study.
    • 28 Jun 2016 According to a Celyad media release, the company will use the results from this trial to optimize the design of the pivotal CHART-2 US trial (Profile 240484).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top